Navigation Links
Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action

piratory disease indications where Prolexys has identified novel therapeutic targets and small molecule compounds active at these targets. Prolexys' ability to identify and validate novel targets is driven by its technological leadership in the field of proteomics and the application of proteomics technologies to its own, and its partners, drug discovery programs. For more information about Prolexys, visit the company's website at http://www.prolexys.com.

About Columbia University: A leading academic and research university, Columbia continually seeks to advance the frontiers of knowledge and to foster a campus community deeply engaged in understanding and addressing the complex global issues of our time. Columbia's extensive public service initiatives, cultural collaborations and community partnerships help define the University's underlying values and mission to educate students to be both leading scholars and informed, engaged citizens. Founded in 1754 as King's College, in the City of New York is the country's fifth oldest institution of higher learning.

CONTACT: Dr. Sudhir Sahasrabudhe, CSO of Prolexys Pharmaceuticals,+1-801-303-1714

Web site: http://www.myriad-proteomics.com/http://www.prolexys.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... CHENGDU, China, Dec. 24, 2014 /PRNewswire/  -- Tianyin ... a pharmaceutical company that specializes in the patented ... and active pharmaceutical ingredients (API) released unaudited preliminary ... year 2015. Fiscal Year 2015 Ended ... was $9.7 million compared with $14.7 million in ...
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... closing in on a "fountain of youth" drug that can ... older adults, a new study suggests. Seniors received a ... that targets a genetic signaling pathway linked to aging and ... The experimental medication, a version of the drug ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Plugin creators ... ProFire 5k. A fully customizable business presentation tool made ... “Adding the ProFire 5k business tool, users can now ... Austin, CEO of Pixel Film Studios. “ProFire 5k gives ... style to add professionalism to a presentation” , Pixel ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and retailer, ... $150 . All these items are brand new; they are ... been updated with the new range of high quality prom ... All iFitDress.com’s designs are made according to the latest trends. ... Every outfit from the company is handpicked by skilled tailors. ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... Association,of Realtors testified at the Senate Finance Committee hearing ... serve the needs of,its self-employed members. Nearly 30 percent ... primary reason - 84 percent of Realtors who do,not ... believe that tax incentives for the self-employed and for ...
... Inc. (APCapital) (Nasdaq: ACAP ) today announced net,income ... for the third,quarter of 2007. For the first nine ... million, or $3.54 per diluted common share. At,September 30, ... on,10,575,799 shares outstanding, an increase of 10.1% from $23.26 ...
... a Phase II Trial to Evaluate an Immunomodulatory Cell ... York, NY October 25, 2007 The ... Osiris Therapeutics, Inc. (NASDAQ:OSIR) to support a Phase II ... to preserve and regenerate insulin-producing cells in patients newly ...
... in Cancer Control, Volunteerism and,Humanitarianism, ATLANTA, ... and dedication have helped reduce the burden ... American Cancer Society for their work,in cancer ... Society, the nation,s largest voluntary health organization, ...
... show Masimo provides unique benefits in pulse oximetry, ... hemodynamic monitoring IRVINE, Calif., Oct. 25 /PRNewswire-FirstCall/ ... and Low Perfusion pulse oximetry,reported that multiple independent ... presented last week at the 2007 American Society ...
... new information that may help to improve the use of ... vessels in tumors, a process called angiogenesis that is critical ... present there are no reliable methods for determining whether they ... a patient will benefit (or not) from treatment. , ...
Cached Medicine News:Health News:Nearly 30 Percent of Realtors(R) Lack Health Insurance 2Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 2Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 3Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 4Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 5Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 6Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 7Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 8Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 9Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 10Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 11Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 12Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 13Health News:JDRF Partners with Osiris to evaluate an immunomodulatory cell therapy product for type 1 diabetes 2Health News:American Cancer Society Honors Outstanding Contributions to Fight Against Cancer 2Health News:American Cancer Society Honors Outstanding Contributions to Fight Against Cancer 3Health News:American Cancer Society Honors Outstanding Contributions to Fight Against Cancer 4Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 2Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 3Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 4Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 5Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 6Health News:Study shows blood markers can help choose best dose for antiangiogenic drugs 2Health News:Study shows blood markers can help choose best dose for antiangiogenic drugs 3
... unique Electro-4 design allows "Four gels in one ... possible to run 200 samples or more in ... four horizontal gels. To ensure even migration, the ... of gels being run. Ideal for high throughput ...
... may be formed directly on the UV-transparent gel ... agarose as it cools, or outside the unit ... Gel is 7.5cm wide 10cm long. Different colors ... (e.g., RNA only). Combs and tape are not ...
... gel is made of high quality PMMA. It features ... protection device.Combs, gel tray and cables are all included ... 6.5x6 (cm), 200 ... 2 (9-well) • 2 ...
... the HE 33 Mini Submarine Unit for nucleic acid ... is designed for very fast separations of DNA restriction ... as a heat-sink. Fill the base with coolant and ... either keeping the unit in a freezer or by ...
Medicine Products: